TryGOLD- Free

BSV portfolio can touch ₹5,000 cr in 3-4 yrs'
Business Standard|July 29, 2024
In one of the biggest pharmaceutical (pharma) deals in recent years, Delhi-based Mankind Pharma acquired Mumbai-headquartered specialty pharma company Bharat Serums and Vaccines (BSV) for ₹13,630 crore on Friday. RAJEEV JUNEJA, managing director (MD) and vice-chairman of Mankind Pharma, spoke to Sohini Das over the phone about the potential of the BSV portfolio to reach a ₹5,000 crore turnover in three to four years with Mankind's marketing prowess. Edited excerpts:
- Sohini Das

Will this deal lead to Mankind Pharma focusing on exports too?

We have been very clear from the beginning that we don't want to get into exports with generic or me-too products. We always wanted products with a high level of entry barriers and complexity.

With the BSV deal, we now have branded products in some cases, there is no competition, and in others, there is limited competition (one or two players). For example, consider the AntiD product that BSV hasnearly 5-7 per cent of Indian mothers are Rh negative (blood group), which amounts to 8-10 million mothers.

Lack of preventive measures can cause brain damage or jaundice in & newborns. The mother needs to take a dose in the third trimester and within 72 hours after delivery with an Rh-positive child. Only 3040 per cent of expecting mothers adhere to this due to lack of awareness. BSV has the world's first and only recombinant for AntiRhoD, which has a valid patent until 2028. It also has vertically integrated in-house cell lines. If anyone tries to make any product of BSV, it would take five to 10 years at least. But we also feel there is huge potential for these products in the Indian market itself. Even after acquiring BSV, 87 per cent of the revenues of the entity will come from India. Wherever we have strong opportunities in the rest of the world, we will pursue them. Our ambition is to become a great company in India.

How do you wish to grow the synergies between BSV and Mankind?

Probably the fastest-growing therapy segment is infertility treatment. People are marrying late, then deciding to have a baby later on in their lives, focusing on careers, stress-myriad factors are affecting fertility.

This story is from the July 29, 2024 edition of Business Standard.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.

This story is from the July 29, 2024 edition of Business Standard.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.

MORE STORIES FROM BUSINESS STANDARDView All
Zomato stock crashes 14% in 2 days after Q3 results
Business Standard

Zomato stock crashes 14% in 2 days after Q3 results

Investors heavily dumped Zomato shares on Tuesday, disappointed with a surprisingly weak performance in the December quarter (Q3FY25).

time-read
2 mins  |
January 22, 2025
Business Standard

Ideal for low-risk investors with goals 1-3 yrs away

Union Mutual Fund recently launched the Union Short Duration Fund, an open-ended short-duration debt scheme.

time-read
2 mins  |
January 22, 2025
SECOND CLASS CRICKET
Business Standard

SECOND CLASS CRICKET

India stars are turning up for Ranji matches. However, with all eyes riveted on the IPL, the first-class championship is in dire need of a booster shot

time-read
5 mins  |
January 22, 2025
e2W Makers Call For GST Rate Cuts, Relook At PM E-DRIVE Plan
Business Standard

e2W Makers Call For GST Rate Cuts, Relook At PM E-DRIVE Plan

With the Union Budget 2025 on the horizon, electric two-wheeler (e2W) players are urging the government to introduce critical policy measures and incentives to revitalise the sector.

time-read
2 mins  |
January 22, 2025
Business Standard

More US energy exports to India likely: Puri

Trump's energy push may lead to increased American crude oil, LNG shipments to the country

time-read
2 mins  |
January 22, 2025
Valuation Woes Negate Q3 Positives for Dixon
Business Standard

Valuation Woes Negate Q3 Positives for Dixon

Shares slump 14%, prompting analysts to maintain cautious stance

time-read
2 mins  |
January 22, 2025
Banks to overhaul terms of engagement with BCs
Business Standard

Banks to overhaul terms of engagement with BCs

A First in 12 Years

time-read
1 min  |
January 22, 2025
NRAI calls for ONDC boost to challenge Zomato and Swiggy
Business Standard

NRAI calls for ONDC boost to challenge Zomato and Swiggy

The National Restaurant Association of India (NRAI), the country's leading restaurateurs' body, has decided to step up pressure on the government-backed Open Network for Digital Commerce (ONDC) to take on Zomato and Swiggy's standalone apps for 10-minute food delivery, Bistro and Snacc.

time-read
1 min  |
January 22, 2025
Challenges Posed by AI Dominate Talks at Davos
Business Standard

Challenges Posed by AI Dominate Talks at Davos

Union Ministers, CMs Unveil India Pavilion, Meet Leaders of Global Companies

time-read
2 mins  |
January 22, 2025
Equities tumble, volatility surges
Business Standard

Equities tumble, volatility surges

A slew of executive orders and announcements on Day 1 turn policymakers, investors cautious

time-read
2 mins  |
January 22, 2025

We use cookies to provide and improve our services. By using our site, you consent to cookies. Learn more